Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation - Sorbonne Université
Article Dans Une Revue Antiviral Research Année : 2019

Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation

Résumé

Epstein-Barr virus (EBV) is a widely distributed gamma-herpesvirus that has been associated with various cancers mainly from lymphocytic and epithelial origin. Although EBV-mediated oncogenesis has been associated with viral oncogenes expressed during latency, a growing set of evidence suggested that antiviral treatments directed against EBV lytic phase may contribute to prevent some forms of cancers, including EBV-positive Post-Transplant Lymphoproliferative Diseases. It is shown here that dipyridamole (DIP), a safe drug with favorable and broad pharmacological properties, inhibits EBV reactivation from B-cell lines. DIP repressed immediate early and early genes expression mostly through its ability to inhibit nucleoside uptake. Considering its wide clinical use, DIP repurposing could shortly be evaluated, alone or in combination with other antivirals, to treat EBV-related diseases where lytic replication plays a deleterious role.
Fichier principal
Vignette du fichier
Thomé et al. - 2019 - Dipyridamole as a new drug to prevent Epstein-Barr.pdf (70.63 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-03001664 , version 1 (12-11-2020)

Identifiants

Citer

Marcos P Thomé, Chloé Borde, Annette K Larsen, Joao A.P. Henriques, Guido Lenz, et al.. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation. Antiviral Research, 2019, 172, pp.104615. ⟨10.1016/j.antiviral.2019.104615⟩. ⟨hal-03001664⟩
274 Consultations
43 Téléchargements

Altmetric

Partager

More